158 related articles for article (PubMed ID: 22816446)
1. Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.
Funk-Keenan J; Sacco J; Wong YY; Rasmussen S; Motsinger-Reif A; Trepanier LA
J Vet Intern Med; 2012; 26(5):1126-33. PubMed ID: 22816446
[TBL] [Abstract][Full Text] [Related]
2. A single-nucleotide polymorphism in the canine cytochrome b
Reinhart JM; Ekena J; Cioffi AC; Trepanier LA
J Vet Pharmacol Ther; 2018 Jun; 41(3):402-408. PubMed ID: 29336038
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.
Sacco JC; Abouraya M; Motsinger-Reif A; Yale SH; McCarty CA; Trepanier LA
Pharmacogenet Genomics; 2012 Oct; 22(10):733-40. PubMed ID: 22850190
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC; Trepanier LA
Pharmacogenet Genomics; 2010 Jan; 20(1):26-37. PubMed ID: 19997042
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women.
Blanke KL; Sacco JC; Millikan RC; Olshan AF; Luo J; Trepanier LA
Cancer Causes Control; 2014 Nov; 25(11):1513-21. PubMed ID: 25225034
[TBL] [Abstract][Full Text] [Related]
6. Familial Congenital Methemoglobinemia in Pomeranian Dogs Caused by a Missense Variant in the NADH-Cytochrome B5 Reductase Gene.
Shino H; Otsuka-Yamasaki Y; Sato T; Ooi K; Inanami O; Sato R; Yamasaki M
J Vet Intern Med; 2018 Jan; 32(1):165-171. PubMed ID: 29356095
[TBL] [Abstract][Full Text] [Related]
7. Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.
Rhoads K; Sacco JC; Drescher N; Wong A; Trepanier LA
Toxicol Sci; 2011 Jun; 121(2):245-56. PubMed ID: 21447608
[TBL] [Abstract][Full Text] [Related]
8. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog.
Trepanier LA
J Vet Pharmacol Ther; 2004 Jun; 27(3):129-38. PubMed ID: 15189298
[TBL] [Abstract][Full Text] [Related]
9. Congenital methemoglobinemia in a dog with a promoter deletion and a nonsynonymous coding variant in the gene encoding cytochrome b₅.
McKenna JA; Sacco J; Son TT; Trepanier LA; Callan MB; Harvey JW; Arndt JW
J Vet Intern Med; 2014; 28(5):1626-31. PubMed ID: 25145387
[No Abstract] [Full Text] [Related]
10. Effect of mutations in porcine CYB5A and CYP17A1 on the metabolism of pregnenolone.
Squires EJ; Gray MA; Lou Y
J Steroid Biochem Mol Biol; 2019 Dec; 195():105469. PubMed ID: 31509771
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in CYB5R3 is associated with methemoglobin levels in preterm infants receiving nitric oxide therapy.
Fuller TD; Spracklen CN; Ryckman KK; Knake LA; Busch TD; Momany AM; Murray JC; Dagle JM
Pediatr Res; 2015 Mar; 77(3):472-6. PubMed ID: 25521918
[TBL] [Abstract][Full Text] [Related]
12. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides.
Trepanier LA; Danhof R; Toll J; Watrous D
J Vet Intern Med; 2003; 17(5):647-52. PubMed ID: 14529130
[TBL] [Abstract][Full Text] [Related]
13. Study of the individual cytochrome b5 and cytochrome b5 reductase domains of Ncb5or reveals a unique heme pocket and a possible role of the CS domain.
Deng B; Parthasarathy S; Wang W; Gibney BR; Battaile KP; Lovell S; Benson DR; Zhu H
J Biol Chem; 2010 Sep; 285(39):30181-91. PubMed ID: 20630863
[TBL] [Abstract][Full Text] [Related]
14. Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.
Bhusari S; Abouraya M; Padilla ML; Pinkerton ME; Drescher NJ; Sacco JC; Trepanier LA
Arch Toxicol; 2010 Aug; 84(8):597-607. PubMed ID: 20221587
[TBL] [Abstract][Full Text] [Related]
15. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.
Knowles S; Shapiro L; Shear NH
Drug Saf; 2001; 24(4):239-47. PubMed ID: 11330653
[TBL] [Abstract][Full Text] [Related]
16. The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs.
Lehmann DF
Drug Metab Lett; 2012 Jun; 6(2):129-33. PubMed ID: 23157194
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel nicotinamide adenine dinucleotide-cytochrome b5 reductase mutation associated with canine hereditary methemoglobinemia.
Otsuka-Yamasaki Y; Inanami O; Shino H; Sato R; Yamasaki M
J Vet Med Sci; 2021 Mar; 83(2):315-321. PubMed ID: 33342963
[TBL] [Abstract][Full Text] [Related]
18. Sulfonamide Hypersensitivity: Fact and Fiction.
Khan DA; Knowles SR; Shear NH
J Allergy Clin Immunol Pract; 2019; 7(7):2116-2123. PubMed ID: 31495421
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites.
Rieder MJ; Uetrecht J; Shear NH; Cannon M; Miller M; Spielberg SP
Ann Intern Med; 1989 Feb; 110(4):286-9. PubMed ID: 2913915
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a novel splice variant of mouse and rat cytochrome b5/cytochrome b5 reductase.
Curry BJ; Roman SD; Wallace CA; Scott R; Miriami E; Aitken RJ
Genomics; 2004 Mar; 83(3):425-38. PubMed ID: 14962668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
